Merck (MRK) Perks
Merck’s (MRK) sales for the last quarter were $6.1 billion, an increase of 6% from the second quarter of 2006. Net income for the second quarter of 2007 was $1,676.4 million, compared to $1,499.3 million in the same quarter a…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Merck’s (MRK) sales for the last quarter were $6.1 billion, an increase of 6% from the second quarter of 2006. Net income for the second quarter of 2007 was $1,676.4 million, compared to $1,499.3 million in the same quarter a year ago.
The company raised full-year 2007 guidance and now anticipates EPS range of $3.00 to $3.10.
WORLDWIDEPRODUCT 2007 SALES----------------------------------- ------------------------------SINGULAIR (Respiratory) $4.0 to $4.3 billionCOZAAR/HYZAAR (Hypertension) $3.2 to $3.5 billionVaccines (as recorded by Merck &Co., Inc.) $3.9 to $4.3 billionFOSAMAX (Osteoporosis) $2.8 to $3.1 billionZOCOR (Cholesterol modifying) $0.6 to $0.9 billionOther reported products* $5.6 to $5.9 billion
Douglas A McIntyre
Contact [email protected] for any questions or corrections.
